HEALIUS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.205 AUD | -1.23% |
|
-3.60% | -26.30% |
| Mar. 06 | Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight | MT |
| Mar. 05 | Australia shares inch lower as miners weigh; GDP data in focus | RE |
| Sales 2024 * | 1.72B 1.11B | Sales 2025 * | 1.8B 1.17B | Capitalization | 875M 567M |
|---|---|---|---|---|---|
| Net income 2024 * | -632M -409M | Net income 2025 * | 26M 16.84M | EV / Sales 2024 * | 1.38 x |
| Net Debt 2024 * | 1.49B 964M | Net Debt 2025 * | 1.42B 919M | EV / Sales 2025 * | 1.27 x |
| P/E ratio 2024 * |
-1.49
x | P/E ratio 2025 * |
29.7
x | Employees | 10,500 |
| Yield 2024 * |
-
| Yield 2025 * |
1.78% | Free-Float | 87.61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Healius Limited
More recommendations
More press releases
More news
| 1 day | -1.23% | ||
| 1 week | -3.60% | ||
| Current month | -9.06% | ||
| 1 month | -9.06% | ||
| 3 months | -12.04% | ||
| 6 months | -34.33% | ||
| Current year | -26.30% |
1 week
1.19
1.30
1 month
1.171.35
Current year
1.091.70
1 year
1.093.27
3 years
1.095.54
5 years
1.095.54
10 years
1.095.54
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Anderson
CEO | Chief Executive Officer | - | 23-02-28 |
| Director of Finance/CFO | - | 20-01-31 | |
Prasad Arav
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gordon Davis
BRD | Director/Board Member | 67 | 15-08-02 |
Kathryn McKenzie
CHM | Chairman | 65 | 21-02-24 |
John Mattick
BRD | Director/Board Member | - | 22-03-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.01% | 7 M€ | +1.36% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 1.205 | -1.23% | 1,504,403 |
| 24-04-29 | 1.22 | +2.09% | 788,403 |
| 24-04-26 | 1.195 | -4.40% | 2,214,822 |
| 24-04-24 | 1.25 | -1.19% | 2,003,466 |
| 24-04-23 | 1.265 | +1.20% | 4,019,028 |
Delayed Quote Australian S.E., April 30, 2024 at 02:10 am EDT
More quotes
Healius Limited is an Australia-based healthcare company. The Company operates through two segments: Pathology and Imaging. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment is a provider of imaging and scanning services at standalone imaging sites, hospitals, and medical centers. The Company has a network of pathology laboratories, collection centers, and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. The Companyâs brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others. The Company provides healthcare services that are accessible and efficient while supporting the coordination and continuity of quality patient care.
Calendar
2024-08-20
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
13
Last Close Price
1.205
AUD
Average target price
1.364
AUD
Spread / Average Target
+13.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.30% | 581M | |
| -16.55% | 8.43B | |
| +39.49% | 3.62B | |
| -38.71% | 2.61B | |
| -8.06% | 2.48B | |
| -7.96% | 2.34B | |
| -13.97% | 1.94B | |
| -19.73% | 1.56B | |
| -40.78% | 1.26B | |
| +8.32% | 1.1B |
- Stock Market
- Equities
- HLS Stock
